These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25457852)

  • 1. Is antiviral drug-induced hepatitis B surface antigen loss durable?
    Wong VW; Wong GL; Chan FK
    Gastroenterology; 2014 Dec; 147(6):1435-6. PubMed ID: 25457852
    [No Abstract]   [Full Text] [Related]  

  • 2. Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?
    Wiegand J; Patel K; Tillmann HL
    Hepatology; 2009 Oct; 50(4):1314; author reply 1314. PubMed ID: 19676132
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of interferon neutralization antibody in the treatment of chronic hepatitis B with interferon].
    CHEN XR; WANG HL; XUAN MX; MAO XG; SUN JG; WAN BM
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):385-6. PubMed ID: 19497208
    [No Abstract]   [Full Text] [Related]  

  • 4. Spontaneous hepatitis B surface antigen seroclearance confers appreciably high rates except in patients with relapse of hepatitis.
    Xin YN; Xuan SY
    Hepatology; 2008 Sep; 48(3):1021-2; author reply 1022. PubMed ID: 18756479
    [No Abstract]   [Full Text] [Related]  

  • 5. Update of chronic hepatitis B.
    Yuan H; Lee WM
    Curr Opin Gastroenterol; 2011 May; 27(3):217-23. PubMed ID: 21423004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A reduction study of seroconversion of HBsAg in chronic hepatitis B patients with HBeAg positive by combination treatment with interferon and lamivudine].
    Yu SL; Qin LY; Wang C; Yu LJ; Guo CY; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):472-3. PubMed ID: 19567034
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic hepatitis B: back to the future with HBsAg.
    Moucari R; Lada O; Marcellin P
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
    [No Abstract]   [Full Text] [Related]  

  • 8. [Are phyllanthus species effective in hepatitis B?].
    Rakowitz B
    Dtsch Med Wochenschr; 2011 Jul; 136(28-29):1460. PubMed ID: 21732258
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis].
    Wang FS; Zhang JY
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):164-6. PubMed ID: 19554778
    [No Abstract]   [Full Text] [Related]  

  • 10. [The clinical significance of hepatitis B virus large surface protein in the diagnosis and treatment of patients with hepatitis B].
    Xie FY; Sun Q; Chen W
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Aug; 27(4):280-2. PubMed ID: 24579475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lamivudine treatment consensus from relative experts in 2003].
    Lamivudine Clinical Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):497-9. PubMed ID: 12939188
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between IgG antibody against the C-terminal region of the preS1 protein of hepatitis B virus and the early response to interferon therapy in chronic hepatitis B].
    Xia GM; Zhang ZH; Wei SF; Gao YF; Zhang TT; Zhang L; Li X
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):1-4. PubMed ID: 20128959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Loss or seroconversion of HBsAg in patients with chronic hepatitis B after treatment with lamivudine: 2 cases report].
    Zhao KK; Miao QL; Bi LN
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):871. PubMed ID: 21138644
    [No Abstract]   [Full Text] [Related]  

  • 15. New therapeutic targets and drugs for the treatment of chronic hepatitis B.
    Fletcher SP; Delaney WE
    Semin Liver Dis; 2013 May; 33(2):130-7. PubMed ID: 23749669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV Chronic hepatitis during chemotherapy - an immune controlled disease.
    Caruntu FA; Gheorghita V
    J Gastrointestin Liver Dis; 2008 Dec; 17(4):445-9. PubMed ID: 19104707
    [No Abstract]   [Full Text] [Related]  

  • 17. [Dynamic change of hepatitis B surface antigen expression in chronic hepatitis B patients during the natural recovery course and the short-term antivirus treatment].
    Liu J; Liu T; Wu YK; Ke WM; Deng ZD; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2013 Aug; 21(8):575-9. PubMed ID: 24119735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis B: a treatment update.
    Wong VW; Chan HL
    Semin Liver Dis; 2013 May; 33(2):122-9. PubMed ID: 23749668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiviral nucleotide-induced dynamic change of HBV DNA and HBsAg and significance of quarterly and annual quantitative measurements over 5-year follow-up of chronic hepatitis B patients].
    Xi HL; Li MR; Bao Y; Yu M; Qin XQ; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):821-4. PubMed ID: 24331690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.